- Stock Movement (Oct 23, 2025): ITGR shares tumbled roughly 37% intraday, trading around $68.67 (down from the prior close of ~$109) [1].
- Q3 Financials: Third-quarter 2025 sales were about $468 million (up 8% year-over-year) [2], with non-GAAP EPS of $1.79 (a 25% YoY increase) [3].
- Revised Guidance: The company trimmed its 2025 revenue outlook to about $1.84–$1.85 billion (from the prior $1.85–$1.88B range) [4]. Full-year adjusted EPS guidance was reaffirmed near $6.29–$6.43 per share [5].
- Analyst Consensus: Wall Street continues to rate ITGR a “Moderate Buy” (nine analysts; 6 Buy/2 Hold, average 12‑mo target ~$135–$137) [6] [7]. (For example, Truist recently cut its 12-month target to $121 [8].)
- Business Role: Integer is a leading medical device contract manufacturer, supplying components and systems for cardiac, vascular, and neurological devices [9]. Its work supports products like pacemakers, neurostimulators and other implantables.
Stock Dives on Oct. 23, 2025
Integer’s stock slumped sharply on Oct. 23 after investors digested the latest financial news. According to Reuters, ITGR was trading around $68.67 (down about 37%) as of mid-day [10] – one of its worst single-day drops on record [11]. For context, the stock had opened near $85 on Oct. 23 against a prior close around $109 [12]. This dramatic fall came despite a largely solid earnings report, reflecting concerns over the company’s revised outlook and upcoming market challenges.
The share plunge outpaced the overall market’s modest gains. Investors noted that Integer had narrowed its revenue guidance for 2025 on Oct. 23 [13], which caught traders off-guard. The company cited “select headwinds” as a factor for slower near-term sales, raising questions about demand next year. In after-market trading following the announcement, ITGR remained under pressure – trading up to 47% below early 2025 highs [14].
Strong Q3 Performance, But Growth Outlook Slows
Integer’s third-quarter results (period ended Sept. 26, 2025) were solid on the top line. Revenue climbed about 8% to $467.7 million [15], meeting Wall Street’s estimates [16]. The gains were driven by its core cardio & vascular segment (up ~15% YoY) and modest growth in cardiac rhythm/neuromodulation products [17] [18]. Non-GAAP operating income rose, and adjusted EBITDA increased roughly 11% vs. a year ago [19].
Adjusted earnings per share stood at $1.79, easily beating the ~$1.68 consensus [20]. As Integer’s CEO Joseph Dziedzic noted, “Integer delivered another strong quarter of growth with sales up 8%… and adjusted EPS growth of 25%,” [21]. In dollar terms, GAAP net income was around $39.7M (vs. $36.3M year-ago) and GAAP EPS $1.11 [22]. In short, the company showed broad strength in Q3 operations.
However, management also issued softer guidance that tempered the news. The full-year 2025 sales forecast was updated to $1.84–$1.854 billion [23], a touch below the previous $1.85–$1.88B range. “Select headwinds are expected to impact our 2026 sales,” Dziedzic warned [24]. Integer reiterated prior profit guidance (non-GAAP EPS $6.29–$6.43), but the modest sales cut signaled slower growth ahead. Reuters summarized the outlook shift: “ITGR trims FY25 rev forecasts to between $1.84B and $1.85B from prior $1.85B–$1.88B” [25]. This disappointment on guidance drove much of the stock’s decline despite the upside in the quarter itself.
Analyst Commentary and Price Targets
Market analysts reacted cautiously to the news. Overall sentiment remains positive long-term (many rate ITGR a Buy), but targets have been coming down. MarketBeat reports that 6 of 9 covering analysts still rate it “Buy” (and 2 “Hold”), giving a consensus 12-month price target of about $135.57 [26]. Similarly, data from Reuters/LSEG note that “nine of 11 brokerages rate the stock ‘buy’ or higher” and quote a median target around $137.50 [27].
Some firms have trimmed their forecasts recently. For example, Truist Financial on Oct. 15 cut its ITGR target to $121 (from $137) but maintained a Buy rating [28]. KeyCorp lowered its target to $133 (from $145) this week [29]. In aggregate, analysts expect only single-digit sales growth in 2026, so many have reduced price targets in light of those headwinds. TipRanks notes “analysts lowered price targets due to expected sales challenges in 2026,” even as the company remains optimistic about longer-term growth [30].
In sum, Wall Street is divided: many still see ITGR as a healthcare growth name, but near-term hurdles have given them pause. The median analyst estimates a stock rebound toward the mid-$130s over the coming year, absent further news.
Integer Holdings: Company Profile
Integer Holdings Corporation is a major medical device contract development and manufacturing organization (CDMO). Based in Plano, Texas, Integer’s business is largely behind the scenes – producing high-precision components and assemblies for leading medical device companies [31]. Its end markets include cardiac rhythm management (e.g. pacemakers, defibrillators), neuromodulation (implanted stimulators for neurological disorders), and cardiovascular and neurovascular devices. Integer’s brands include Greatbatch Medical and Lake Region Medical.
In practical terms, Integer often works with global device makers (OEMs) to design and build parts like implantable batteries, catheters, lead systems, and surgical instruments. As a result, its fortunes are tied to broader trends in medical device spending and innovation. Even with the near-term headwinds noted, the company emphasizes its “strong product development pipeline” and expects to outgrow the market again by 2027 [32].
What’s Ahead for ITGR
Going forward, investors will watch several factors. Key will be Integer’s earnings calls and commentary on 2026 demand – whether the cited headwinds are temporary (such as supply-chain or inventory corrections) or signs of weaker end-market demand. Analysts will update models on how fast Integer can return to its historical growth rates. For now, the sharply lower stock price partly reflects reduced earnings estimates.
Despite today’s volatility, the consensus remains cautiously bullish on the longer-term outlook. Nine brokers still call it a buy, and the stock trades at a price-to-earnings multiple near the mid-teens (forward) [33] [34]. If Integer can resume 7–8% organic growth and execute on higher-margin products, many analysts believe the share price could recover towards the $130–140 range in the next 12–18 months.
In the meantime, October 23, 2025 will be remembered as a sell-off day for Integer – a reminder that even well-performing companies can see steep stock moves when forecasts shift. Investors and analysts alike will be closely parsing every subsequent report and guidance update from Integer as it navigates this slowdown and works to resume stronger growth in future years.
Sources: Integer Holdings IR releases, Reuters, MarketBeat, TipRanks, StockNews/FinancialContent analysis [35] [36] [37] [38].
References
1. www.reuters.com, 2. investor.integer.net, 3. investor.integer.net, 4. www.tradingview.com, 5. investor.integer.net, 6. www.marketbeat.com, 7. www.tradingview.com, 8. www.marketbeat.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.tradingview.com, 12. www.reuters.com, 13. www.tradingview.com, 14. www.tradingview.com, 15. investor.integer.net, 16. markets.financialcontent.com, 17. www.stocktitan.net, 18. investor.integer.net, 19. investor.integer.net, 20. markets.financialcontent.com, 21. investor.integer.net, 22. investor.integer.net, 23. investor.integer.net, 24. investor.integer.net, 25. www.tradingview.com, 26. www.marketbeat.com, 27. www.tradingview.com, 28. www.marketbeat.com, 29. www.marketbeat.com, 30. www.tipranks.com, 31. www.reuters.com, 32. investor.integer.net, 33. www.reuters.com, 34. www.marketbeat.com, 35. investor.integer.net, 36. www.tradingview.com, 37. www.marketbeat.com, 38. www.tipranks.com
